2014
Insight and attitudes towards medication among inpatients with chronic schizophrenia in the US and China
Mohamed S, Rosenheck R, He H, Yuping N. Insight and attitudes towards medication among inpatients with chronic schizophrenia in the US and China. Social Psychiatry And Psychiatric Epidemiology 2014, 49: 1063-1070. PMID: 24549835, DOI: 10.1007/s00127-014-0824-1.Peer-Reviewed Original ResearchConceptsDrug Attitude InventorySchizophrenia symptomsPsychiatric hospitalOverall severityMeasures of insightGuangzhou Psychiatric HospitalTime of admissionBenefits of medicationsLarge psychiatric hospitalNegative Syndrome ScaleTreatment Attitudes QuestionnaireSymptoms of schizophreniaAcceptance of medicationHospitalized patientsAntipsychotic treatmentDAI scoresChronic schizophreniaMedicationsAnalysis of covarianceSyndrome ScaleMental illnessBivariate analysisSymptomsLarger studySchizophrenia
2013
Adding antidepressants to antipsychotics for treatment of subsyndromal depressive symptoms in schizophrenia: Impact on positive and negative symptoms
Vahia IV, Lanouette NM, Golshan S, Fellows I, Mohamed S, Kasckow JW, Zisook S. Adding antidepressants to antipsychotics for treatment of subsyndromal depressive symptoms in schizophrenia: Impact on positive and negative symptoms. Indian Journal Of Psychiatry 2013, 55: 144-148. PMID: 23825848, PMCID: PMC3696237, DOI: 10.4103/0019-5545.111452.Peer-Reviewed Original ResearchAnti-psychotic medicationSubsyndromal depressionNegative symptomsDepressive symptomsSchizoaffective disorderNegative Syndrome Scale (PANSS) scoresPANSS negative symptom scoreFlexible-dose treatmentSchizophrenia/schizoaffective disorderSubsyndromal depressive symptomsPANSS positive scoreNegative symptom scoresAntidepressant augmentationPlacebo augmentationSymptom scoresCitalopram groupStudy criteriaTreatment groupsAnalysis of covarianceScale scoreSymptomsCitalopramSchizophreniaPositive scoreMedications
2009
Off-Label Use of Antipsychotic Medications in the Department of Veterans Affairs Health Care System
Leslie DL, Mohamed S, Rosenheck RA. Off-Label Use of Antipsychotic Medications in the Department of Veterans Affairs Health Care System. Psychiatric Services 2009, 60: 1175-1181. PMID: 19723731, DOI: 10.1176/ps.2009.60.9.1175.Peer-Reviewed Original ResearchConceptsAntipsychotic medicationLabel useLogistic regression modelsBipolar disorderVeterans Affairs Health Care SystemVeterans AffairsMultivariate logistic regression modelVA administrative databasesHalf of patientsFirst-generation antipsychoticsOff-label useSevere side effectsMental illness diagnosisPosttraumatic stress disorderHealth care systemClinical characteristicsRegression modelsAntipsychotic useVA patientsAdministrative databasesMinor depressionMajor depressionHigher oddsMedicationsSide effectsUse of antipsychotics in the treatment of major depressive disorder in the U.S. Department of Veterans Affairs.
Mohamed S, Leslie DL, Rosenheck RA. Use of antipsychotics in the treatment of major depressive disorder in the U.S. Department of Veterans Affairs. The Journal Of Clinical Psychiatry 2009, 70: 906-12. PMID: 19422760, DOI: 10.4088/jcp.08m04450.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAged, 80 and overAntidepressive AgentsAntipsychotic AgentsComorbidityDepressive Disorder, MajorDose-Response Relationship, DrugDrug Therapy, CombinationDrug UtilizationFemaleHospitals, VeteransHumansMaleMiddle AgedUnited StatesUnited States Food and Drug AdministrationVeteransConceptsMajor depressive disorderTreatment of MDDAntipsychotic medicationDepressive disorderService useMental health service useVeterans Affairs patientsUse of antipsychoticsHealth service useComorbid mental illnessDrug Administration approvalLong-term safetyRecent U.S. FoodFirst antipsychoticAntipsychotic dosesAntipsychotic prescriptionsPsychiatric comorbidityComorbid schizophreniaMale genderAdministration approvalVeteran characteristicsMedicationsSchizoaffective disorderAntipsychoticsBipolar disorder
2008
Cross-sectional and Longitudinal Relationships Between Insight and Attitudes Toward Medication and Clinical Outcomes in Chronic Schizophrenia
Mohamed S, Rosenheck R, McEvoy J, Swartz M, Stroup S, Lieberman JA. Cross-sectional and Longitudinal Relationships Between Insight and Attitudes Toward Medication and Clinical Outcomes in Chronic Schizophrenia. Schizophrenia Bulletin 2008, 35: 336-346. PMID: 18586692, PMCID: PMC2659303, DOI: 10.1093/schbul/sbn067.Peer-Reviewed Original ResearchConceptsPositive medication attitudesMedication attitudesSymptoms of schizophreniaSchizophrenia symptomsGreater medication complianceDrug Attitude InventoryRelationship of insightClinical Antipsychotic TrialsTreatment Attitudes QuestionnaireGreater patient understandingLevel of depressionMixed model regression analysisLower symptom levelsRecovery-oriented servicesClinical outcomesMedication adherenceMedication complianceChronic schizophreniaAntipsychotic TrialsPatient understandingModel regression analysisMedicationsCommunity functioningPsychosocial rehabilitationSymptoms
1999
Will the novel antipsychotics significantly ameliorate neuropsychological deficits and improve adaptive functioning in schizophrenia?
HAWKINS KA, MOHAMED S, WOODS SW. Will the novel antipsychotics significantly ameliorate neuropsychological deficits and improve adaptive functioning in schizophrenia? Psychological Medicine 1999, 29: 1-8. PMID: 10077288, DOI: 10.1017/s0033291798006990.Peer-Reviewed Original ResearchConceptsNovel antipsychoticsNegative symptomsNeuropsychological deficitsSevere psychiatric illnessNew antipsychotic medicationsTreatment of schizophreniaCognitive outcome dataAntipsychotic medicationConventional neurolepticsNeurodevelopmental aberrationsClinical effectivenessNew antipsychoticsUnderlying pathophysiologyClinical reasonsPsychiatric illnessImproved complianceOutcome dataFunctional capacityNeurological effectsAntipsychoticsAuditory hallucinationsNeurocognitive changesMedicationsNeural tissueSymptoms